PRIMA-1 inhibits Y220C p53 amyloid aggregation and synergizes with cisplatin in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide. Although many therapeutic options are available, several factors, including the presence of p53 mutations, impact tumor development and therapeutic resistance. TP53 is the second most frequently mutated gen...

Descripción completa

Detalles Bibliográficos
Autores principales: Paz, Mariana M., Ferretti, Giulia D. S., Martins-Dinis, Mafalda M. C., Ferreira, Beatriz I. S., Faier-Pereira, Amanda, Barnoud, Thibaut, Moreira, Otacilio C., Silva, Jerson L., Cordeiro, Yraima, Rangel, Luciana P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Molecular Biosciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123287/
https://www.ncbi.nlm.nih.gov/pubmed/37101558
http://dx.doi.org/10.3389/fmolb.2023.1165132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123287/
https://www.ncbi.nlm.nih.gov/pubmed/37101558
http://dx.doi.org/10.3389/fmolb.2023.1165132

Ejemplares similares